Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 9016148, 6 pages
https://doi.org/10.1155/2017/9016148
Research Article

Prevalence of Positive Diabetes-Associated Autoantibodies among Type 2 Diabetes and Related Metabolic and Inflammatory Differences in a Sample of the Bulgarian Population

1University Hospital Alexandrovska, Clinic of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Medical University-Sofia, Sofia, Bulgaria
2University Hospital St. Ivan Rilski, Laboratory of Clinical Immunology, Department of Clinical Immunology, Faculty of Medicine, Medical University-Sofia, Sofia, Bulgaria
3University Hospital Alexandrovska, Central Clinical Laboratory, Department of Clinical Laboratory, Faculty of Medicine, Medical University-Sofia, Sofia, Bulgaria

Correspondence should be addressed to Emanuela Tsvetkova Zaharieva; gb.vba@e_aveirahaz

Received 16 February 2017; Revised 22 March 2017; Accepted 11 April 2017; Published 9 May 2017

Academic Editor: Marco Songini

Copyright © 2017 Emanuela Tsvetkova Zaharieva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Z. Zimmet, “The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography,” Diabetes Care, vol. 18, no. 7, pp. 1050–1064, 1995. View at Publisher · View at Google Scholar
  2. J. P. Palmer and I. B. Hirsch, “What’s in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes,” Diabetes Care, vol. 26, no. 2, pp. 536–538, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Stenström, A. Gottsäter, E. Bakhtadze, B. Berger, and G. Sundkvist, “Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment,” Diabetes, vol. 54, Supplement 2, pp. S68–S72, 2005. View at Google Scholar
  4. M. J. Redondo, “LADA: time for a new definition,” Diabetes, vol. 62, no. 2, pp. 339–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. B. M. Brooks-Worrell and J. P. Palmer, “Latent autoimmune diabetes in adults,” in Immunoendocrinology: Scientific and Clinical Aspects (Contemporary Endocrinology), pp. 315–330, Humana Press, New York, 2011. View at Google Scholar
  6. R. Turner, I. Stratton, V. Horton et al., “UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK prospective diabetes study group,” Lancet, vol. 350, no. 9087, pp. 1288–1293, 1997. View at Google Scholar
  7. V. Lampasona, A. Petrone, C. Tiberti et al., “Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes,” Diabetes Care, vol. 33, no. 1, pp. 104–108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Tiberti, C. Giordano, M. Locatelli et al., “Dotta F identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2,” Diabetes, vol. 57, no. 5, pp. 1276–1283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Laugesen, J. A. Østergaard, and R. D. Leslie, “Danish diabetes academy workshop and workshop speakers. Latent autoimmune diabetes of the adult: current knowledge and uncertainty,” Diabetic Medicine, vol. 32, no. 7, pp. 843–852, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Cervin, V. Lyssenko, E. Bakhtadze et al., “Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes,” Diabetes, vol. 57, no. 5, pp. 1433–1437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. N. Pham, M. I. Hawa, C. Pfleger et al., “Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: action LADA 4,” Diabetologia, vol. 54, no. 7, pp. 1630–1638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Strom, B. Menart, M. C. Simon et al., “Cellular interferon-γ and interleukin-13 immune reactivity in type 1, type 2 and latent autoimmune diabetes: action LADA 6,” Cytokine, vol. 58, no. 2, pp. 148–151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. W. Deutekom, R. J. Heine, and S. Simsek, “The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus,” Diabetic Medicine, vol. 25, no. 2, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. M. Davis, A. D. Wright, Z. M. Mehta et al., “Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70),” Diabetologia, vol. 48, no. 4, pp. 695–702, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. I. Hawa, C. Thivolet, D. Mauricio et al., “Metabolic syndrome and autoimmune diabetes: action LADA 3,” Diabetes Care, vol. 32, no. 1, pp. 160–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Juneja, I. B. Hirsch, R. G. Naik, B. M. Brooks-Worrell, C. J. Greenbaum, and J. P. Palmer, “Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes,” Metabolism, vol. 50, no. 9, pp. 1008–1013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. H. K. Chiu, E. C. Tsai, R. Juneja et al., “Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 77, no. 2, pp. 237–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. World Medical Association, “World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects,” Journal of the American Medical Association, vol. 310, no. 20, pp. 2191–2194, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, Supplement 1, pp. S62–S69, 2010. View at Google Scholar
  20. C. Törn, P. W. Mueller, M. Schlosser, E. Bonifacio, and P. J. Bingley, “Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2,” Diabetologia, vol. 51, no. 5, pp. 846–852, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. G. Hills Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Maioli, G. M. Pes, G. Delitala et al., “Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults,” European Journal of Endocrinology, vol. 163, no. 4, pp. 541–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Lohmann, K. Kellner, H. J. Verlohren et al., “Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA),” Diabetologia, vol. 44, no. 8, pp. 1005–1010, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews. Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. M. Brooks-Worrell, J. L. Reichow, A. Goel, H. Ismail, and J. P. Palmer, “Identification of autoantibody-negative autoimmune type 2 diabetic patients,” Diabetes Care, vol. 34, no. 1, pp. 168–173, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Chaillous, B. Bouhanick, V. Kerlan et al., “Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control,” Diabetes & Metabolism, vol. 36, no. 1, pp. 64–70, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Cernea, R. Buzzetti, and P. Pozzilli, “Beta-cell protection and therapy for latent autoimmune diabetes in adults,” Diabetes Care, vol. 32, Supplement 2, pp. S246–S252, 2009. View at Publisher · View at Google Scholar
  28. S. Brophy, H. Davies, S. Mannan, H. Brunt, and R. Williams, “Interventions for latent autoimmune diabetes (LADA) in adults,” Cochrane Database of Systematic Reviews, vol. 9, no. 9, p. CD006165, 2011. View at Publisher · View at Google Scholar
  29. M. Thunander, H. Thorgeirsson, C. Törn, C. Petersson, and M. Landin-Olsson, “β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up,” European Journal of Endocrinology, vol. 64, no. 2, pp. 239–245, 2011. View at Publisher · View at Google Scholar · View at Scopus